Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with
cancers resistant to traditional therapies. Natural or genetically modified OVs are …

Natural killer (NK) cells, a crucial component of the innate immune system, have long been
of clinical interest for their antitumor properties. Almost every aspect of NK cell immunity is …

Cancer immunotherapy and vaccine development have significantly improved the fight
against cancers. Despite these advancements, challenges remain, particularly in the clinical …

Dysregulation of the Notch signaling pathway, which is highly conserved across species,
can drive aberrant epigenetic modification, transcription, and translation. Defective gene …

Bi-, tri-and multispecific antibodies have enabled the development of targeted cancer
immunotherapies redirecting immune effector cells to eliminate malignantly transformed …

Chemokines such as CC motif ligand 5 (CCL5) regulate immune cell trafficking in the tumor
microenvironment (TME) and govern tumor development, making them promising targets for …

Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have
revolutionized treatment for several cancer types over the past decade. Despite this success …

Cancer immunotherapy has opened a new landscape in cancer treatment, however, the
poor specificity and resistance of most targeted therapeutics have limited their therapeutic …

Gene-engineered immune cell therapies have partially transformed cancer treatment, as
exemplified by the use of chimeric antigen receptor (CAR)-T cells in certain hematologic …

The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …